YAMAHA
12.5.2023 04:01:33 CEST | Business Wire | Press release
In cooperation with the Delhi Board of School Education, Yamaha Corporation (below, "Yamaha") introduced Japanese-style instrumental music education using recorders for grade V students at ten public primary schools in India in April. Programs using recorders and keyboards have been offered as extra-curriculum activities at private primary schools in India since 2017, but this is the first time a program will be offered as part of public primary school classes. The program offered by Yamaha not only includes technical recorder instruction, but also incorporates groupwork and discussion within classes to cultivate mutual understanding. Preceding the start of the classes, music teacher training is being conducted with an emphasis on using a holistic learning approach. Yamaha aims to expand the program to more schools in Delhi in the future. “Introduction of Japanese-style music education in primary education in India” was adopted by MEXT as a 2022 EDU-Port Japan*1 Supported Project.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230511005424/en/
Classes at public primary school in India
About School Project
As a comprehensive musical instruments manufacturer, Yamaha has been promoting the advantages of music and instrumental music education to music education sites around the world. In particular, Yamaha’s School Project, which it has been developing principally in emerging countries since 2015, is an initiative with the aim of popularizing activities using music and musical instruments in public education to convey the joy of music and musical instruments. To date, Yamaha has provided a total of 2,020,000 children (as of March 2023) in seven countries—Malaysia, Indonesia, Vietnam, India, Brazil, the United Arab Emirates, and Egypt—with opportunities to learn instrumental music, helping to create an environment where children can enjoy music and playing musical instruments.
Through this activity, Yamaha aims to contribute to Goal 4: "Quality Education," Goal 10: “Reduced Inequalities,” Goal 16: “Peace, Justice and Strong Institutions,” and Goal 17: "Partnerships for the Goals" of the Sustainable Development Goals (SDGs), as well as to develop children's non-cognitive skills through music and instrumental music education and to formulate a business model for musical education activities tailored to the educational situation in schools around the world.
Comments from Yasuhiro Yonehara, First Secretary, Embassy of Japan in India
Walking through the streets of India, one can hear music along with the bustling of the city. In Bollywood films, actors can be seen dancing joyfully to upbeat songs. Indian people are very familiar with music, and I feel that music is an integral part of their lives. How exciting it is when Indian children pick up a recorder, an unfamiliar instrument, learn to play it and create music. I sincerely wish that this initiative, which is making this possible, will be a huge success.
*1 EDU-Port Japan is a “public-private, nationwide” initiative to introduce Japanese-style education overseas using the public-private collaborative platform, supported by Japan’s Ministry of Education, Culture, Sports, Science and Technology (MEXT).
https://www.yamaha.com/en/about/activities/school_project/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230511005424/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release
Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release
The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release
Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo
Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release
Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets. “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.” Throughout his career, Dan has held senior leadership roles i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
